EphA2 blockade enhances the anti-endothelial effect of radiation and inhibits irradiated tumor cell-induced migration of endothelial cells

Thoracic Cancer

Volumn 1, Issue 4, 2010, Pages 153-162

  Fokas, Emmanouil ^a   Kamlah, Florentine ^a   Hänze, Jörg ^b   Engenhart Cabillic, Rita ^a   Rose, Frank ^a   An, Han Xiang ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

A549 cells; Angiogenesis; Endothelial cells; EphA2; Irradiation; VEGF

Indexed keywords

EPHRIN RECEPTOR A2; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL STRAIN MCF 7; CELL SURVIVAL; CHIMERA; COCULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IONIZING RADIATION; MICROVASCULAR ENDOTHELIAL CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; TUMOR CELL; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 84856509985     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/j.1759-7714.2010.00029.x     Document Type: Article

References (42)

1. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039-49.
2. O'Reilly MS. The interaction of radiation therapy and antiangiogenic therapy. Cancer J 2008; 14: 207-13.
3. O'Reilly MS. Radiation combined with antiangiogenic and antivascular agents. Semin Radiat Oncol 2006; 16: 45-50.
4. Garcia-Barros M, Paris F, Cordon-Cardo C etal. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300: 1155-9.
5. Gorski DH, Beckett MA, Jaskowiak NT etal. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999; 59: 3374-8.
6. Abdollahi A, Lipson KE, Han X etal. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 2003; 63: 3755-63.
7. Dewhirst MW. Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res 2009; 172: 653-65.
8. Chung YL, Jian JJ, Cheng SH etal. Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: implications for radiotherapy of hepatocellular carcinoma. Clin Cancer Res 2006; 12: 2706-15.
9. Geng L, Donnelly E, McMahon G etal. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001; 61: 2413-19.
10. Duda DG, Jain RK, Willett CG. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 2007; 25: 4033-42.
11. O'Reilly MS. Antiangiogenesis and vascular endothelial growth factor/vascular endothelial growth factor receptor targeting as part of a combined-modality approach to the treatment of cancer. Int J Radiat Oncol Biol Phys 2007; 69 (Suppl.): S64-6.
12. Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 2003; 9: 1957-71.
13. Jain RK. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer 2008; 8: 309-16.
14. Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009; 15: 5020-5.
15. Jain RK, Duda DG, Willett CG etal. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009; 6: 327-38.
16. Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008; 133: 38-52.
17. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010; 10: 165-80.
18. Chen J, Zhuang G, Frieden L, Debinski W. Eph receptors and Ephrins in cancer: common themes and controversies. Cancer Res 2008; 68: 10031-3.
19. Dobrzanski P, Hunter K, Jones-Bolin S etal. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res 2004; 64: 910-19.
20. Cheng N, Brantley DM, Liu H etal. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 2002; 1: 2-11.
21. Hess AR, Seftor EA, Gardner LM etal. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 2001; 61: 3250-5.
22. Landen CN Jr, Lu C, Han LY etal. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst 2006; 98: 1558-70.
23. Fokas E, Hanze J, Kamlah F etal. Irradiation-dependent effects on tumor perfusion and endogenous and exogenous hypoxia markers in an A549 xenograft model. Int J Radiat Oncol Biol Phys 2010; 77: 1500-8.
24. Brantley-Sieders DM, Fang WB, Hicks DJ, Zhuang G, Shyr Y, Chen J. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J 2005; 19: 1884-6.
25. Brantley-Sieders DM, Caughron J, Hicks D, Pozzi A, Ruiz JC, Chen J. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J Cell Sci 2004; 117 (Pt 10): 2037-49.
26. Cheng N, Brantley D, Fang WB etal. Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. Neoplasia 2003; 5: 445-56.
27. Brantley-Sieders DM, Zhuang G, Hicks D etal. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 2008; 118: 64-78.
28. Brantley-Sieders DM, Fang WB, Hwang Y, Hicks D, Ephrin CJ. A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Cancer Res 2006; 66: 10315-24.
29. Brantley DM, Cheng N, Thompson EJ etal. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002; 21: 7011-26.
30. Heroult M, Schaffner F, Augustin HG. Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. Exp Cell Res 2006; 312: 642-50.
31. Kinch MS, Moore MB, Harpole DH Jr. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 2003; 9: 613-18.
32. Brannan JM, Dong W, Prudkin L etal. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res 2009; 15: 4423-30.
33. Park CM, Park MJ, Kwak HJ etal. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res 2006; 66: 8511-19.
34. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008; 8: 425-37.
35. Abdollahi A, Griggs DW, Zieher H etal. Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005; 11: 6270-9.
36. Erman M, Moretti L, Soria JC, Le Chevalier T, Van Houtte P. Adjuvant chemotherapy and radiotherapy in non-small cell lung cancer. Semin Radiat Oncol 2004; 14: 315-21.
37. Li J, Huang S, Armstrong EA, Fowler JF, Harari PM. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. Int J Radiat Oncol Biol Phys 2005; 62: 1477-85.
38. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603.
39. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309.
40. Zhuang G, Brantley-Sieders DM, Vaught D etal. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res 2010; 70: 299-308.
41. Nojiri K, Iwakawa M, Ichikawa Y etal. The proangiogenic factor ephrin-A1 is up-regulated in radioresistant murine tumor by irradiation. Exp Biol Med (Maywood) 2009; 234: 112-22.
42. Huang J, Soffer SZ, Kim ES etal. Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res 2004; 2: 36-42.